Esta página aún no ha sido traducida al español. Mientras tanto, te mostramos la versión en inglés con la navegación y pie de página en español. El contenido completo en español estará disponible pronto.
Evidence-based research context for mainstream and longevity-relevant medications — including 10 new Route A crossover compounds: cognitive enhancers, PDE5 inhibitors, GI protectants, thyroid agents, NSAIDs, statins, prostate management, SSRIs, SERMs, and respiratory support. For research use only.
Check medication + peptide interactions. Covers cardiovascular, psychiatric, diabetes, and liver drug interactions. No login.
Track hormones (testosterone, TSH, T3/T4, insulin), metabolic markers (HbA1c, fasting glucose, lipids), liver enzymes, and cardiovascular markers. Our Bloodwork Interpreter covers 27 panels with medication-specific context.
Wakefulness agents with dopamine reuptake inhibition. Cognitive performance under sleep deprivation. CYP3A4 induction — critical interaction with oral AAS liver load.
Read profile → CardiovascularOriginal PDE5 inhibitor — 4-hour half-life, endothelial function improvement, PAH research. Absolute nitrate contraindication including poppers. AAS-induced vascular dysfunction context.
Read profile → GI ProtectionGI protection during oral AAS cycles. H+/K+-ATPase irreversible inhibition. CYP2C19 polymorphism affects efficacy. Pantoprazole preferred when drug interactions matter.
Read profile → ThyroidDirect T3 receptor activation for metabolic rate manipulation during cuts. AAS + T3 stack protocols. Cardiac monitoring mandatory. Muscle catabolism risk at supraphysiological doses.
Read profile → MusculoskeletalCOX-2 selective NSAID for joint pain management on cycle. Nephrotoxicity risk compounded by AAS-induced hemodynamic changes. PPI co-administration required. Creatinine monitoring.
Read profile → CardiovascularDeep-dive lipid management for AAS-induced dyslipidemia. HMG-CoA reductase inhibition, LDL reduction 35–55%. CYP3A4 substrate — myopathy risk with inhibitors. LFT monitoring with oral AAS.
Read profile → UrologicalAlpha-1A blocker for AAS-induced prostate enlargement. Retrograde ejaculation signature side effect. IFIS warning for cataract surgery. PDE5 inhibitor interaction monitoring.
Read profile → PsychiatricSSRIs for mental health on cycle and post-cycle depression. Serotonin-hormone interactions. Sexual dysfunction compounding AAS effects. Sertraline inhibits tamoxifen activation (CYP2D6).
Read profile → SERM / GynoClinical gynecomastia reversal protocols at 60mg/day. Superior to tamoxifen in controlled comparisons (86% vs 41% regression). DVT risk compounded by polycythemia. Stage assessment before treatment.
Read profile → RespiratoryLeukotriene receptor antagonist for exercise-induced bronchoconstriction. Cardiorespiratory support for endurance athletes on compounds. FDA neuropsychiatric black box (2020) — baseline mental health assessment required.
Read profile →HPA axis suppression, delivery methods (IM, SC, topical, pellets), monitoring requirements, and protocol structures used in research contexts. Key bloodwork: total/free testosterone, estradiol, hematocrit, LH, FSH.
Deep dive coming →Aromatization mechanisms, estradiol monitoring targets, AI co-administration (anastrozole, exemestane), and why estrogen management is inseparable from TRT protocol research.
Deep dive coming →Testicular atrophy mechanisms, HCG co-administration to maintain LH stimulus, and research context for fertility preservation in TRT protocols. Bloodwork: LH, FSH, semen analysis context.
Deep dive coming →GLP-1 receptor agonist mechanism, once-weekly dosing pharmacokinetics, metabolic and cardiovascular outcomes in research literature. Monitoring: HbA1c, fasting glucose, lipid panel, kidney function.
Deep dive coming →Dual GLP-1 / GIP receptor agonist with superior efficacy over semaglutide in head-to-head trials. Mechanism comparison, metabolic outcomes, and monitoring protocol context.
Deep dive coming →Lean mass loss during GLP-1 treatment, research on resistance training + protein intake as preservation strategies, and peptide co-administration research context (BPC-157, IGF-1 LR3).
Deep dive coming →AMPK pathway activation, mTOR suppression, mitochondrial complex I inhibition, and cellular senescence mechanisms. The TAME (Targeting Aging with Metformin) trial rationale and current literature status.
Deep dive coming →Research debate: Metformin blunts exercise-induced mTOR signaling and muscle protein synthesis. Evidence review, timing protocols used in research, and NAD+ implications (B12 monitoring required).
Deep dive coming →T4 → T3 conversion via deiodinase enzymes, TSH feedback loop, dosing context from research literature, and required monitoring panel: TSH, free T4, free T3, reverse T3.
Deep dive coming →Direct T3 receptor activation, pharmacokinetics vs T4, combination T4/T3 research context, and thyroid optimization protocols. Monitoring: free T3, reverse T3, resting HR, basal temperature.
Deep dive coming →Research context for thyroid function in the context of GH secretagogue use (GH raises T4 conversion), ipamorelin/CJC-1295 protocols, and metabolic rate considerations.
Deep dive coming →ACE inhibitors, ARBs, calcium channel blockers, and beta-blockers — mechanisms, relevant bloodwork (BMP: creatinine, potassium, BUN), and research context for on-cycle cardiovascular management.
Deep dive coming →Mechanisms of AAS-induced BP elevation (hematocrit increase, RAAS activation, fluid retention), monitoring targets, and research literature on mitigation strategies.
Deep dive coming →AAS suppression of HDL, LDL elevation mechanisms, statin research context (atorvastatin, rosuvastatin), and lipid monitoring protocols. Bloodwork: full lipid panel, LDL-P, ApoB.
Deep dive coming →Comprehensive panel reference: what to order for TRT, GLP-1, AAS, longevity stacks, and thyroid protocols. Timing considerations, fasting requirements, and lab frequency guidelines.
Deep dive coming →Why "normal" lab ranges differ from optimization targets, how to contextualize outliers, and when values warrant protocol adjustments in research settings. Cross-references Bloodwork Interpreter tool.
Deep dive coming →Don't wait for the article. Our Bloodwork Interpreter is live now — 27 markers across 7 panels with medication-specific context, pattern detection, and priority flags.
Open tool →